GlycoMark (1,5-AG): How to Interpret Your Result

What Is GlycoMark (1,5-AG) and Why Does It Matter for Women?

GlycoMark measures 1,5-anhydroglucitol, a naturally occurring sugar-like compound found in food and continuously circulating in your blood. Under normal glucose conditions, 1,5-AG is filtered by the kidney and almost completely reabsorbed, so blood levels stay steady. When glucose rises above roughly 180 mg/dL, glucose floods the renal tubules and competes with 1,5-AG for reabsorption. 1,5-AG spills into urine, and blood levels fall. Because that competition resolves quickly once glucose normalizes, the marker rebounds within days, making it uniquely sensitive to short-term glucose excursions.

Why A1c Is Not Enough

A1c averages glucose over 8 to 12 weeks, which means frequent post-meal spikes can hide behind an otherwise acceptable number. A woman can have an A1c of 6.2% and still experience multiple daily excursions above 180 mg/dL. Research published in Diabetes Care found that 1,5-AG identified postprandial hyperglycemia in patients with near-normal A1c that would have otherwise gone undetected. GlycoMark fills that gap by capturing the previous one to two weeks of glucose behavior, essentially acting as a short-window glycemic diary.

The Renal Threshold: The Rule That Drives Everything

Every interpretation of GlycoMark rests on one biological rule: 1,5-AG only falls when glucose exceeds the renal threshold, approximately 180 mg/dL. Mild fasting hyperglycemia in the 130-160 mg/dL range may not lower 1,5-AG at all. This means GlycoMark is not designed to screen for mild type 2 diabetes; it is designed to detect spikes. Keep that distinction clear when reading your result.

What Is a Normal GlycoMark Range?

For non-pregnant women without kidney disease or SGLT2 inhibitor use, a 1,5-AG level above 10 mcg/mL is generally considered within the reference range. The FDA-cleared GlycoMark assay package insert defines values >10 mcg/mL as normal and <6 mcg/mL as consistent with frequent hyperglycemic excursions.

How the Numbers Break Down

| Result (mcg/mL) | What It Likely Means | |---|---| | >10 | Glucose rarely exceeding 180 mg/dL; good short-term control | | 6-10 | Borderline; some excursions above threshold likely | | <6 | Frequent glucose spikes; clinically significant postprandial hyperglycemia | | <2-3 | Consistent with poorly controlled diabetes |

These cut-points apply to women who are not pregnant and not using an SGLT2 inhibitor such as empagliflozin or dapagliflozin. Both conditions invalidate the standard reference range, as described below.

Does Sex Affect the Reference Range?

Studies in predominantly non-pregnant adult populations have not established a meaningfully different reference range by sex. One analysis in the Journal of Diabetes Science and Technology noted that GlycoMark values trend slightly lower in women of reproductive age compared to age-matched men, though the difference was not clinically significant in that dataset. Larger, female-specific normative data are sparse. This is exactly the kind of evidence gap described in Rule W6: the GlycoMark assay was not validated in cohorts stratified by menstrual cycle phase, hormonal contraception status, or menopausal stage. What exists is extrapolated from mixed-sex or predominantly male cohorts.

How Hormones and Life Stage Change Your GlycoMark

This is where GlycoMark interpretation gets genuinely different for women. Your hormonal environment directly shapes insulin sensitivity, postprandial glucose, and therefore 1,5-AG levels.

Reproductive Years and the Menstrual Cycle

Insulin sensitivity fluctuates across the cycle. In the luteal phase (days 15-28), progesterone reduces insulin sensitivity, and postprandial glucose tends to run higher. Women with type 1 diabetes have long observed that insulin requirements increase before menstruation. A study in Diabetes Care documented luteal-phase increases in mean glucose of approximately 10-15 mg/dL compared to the follicular phase in women with type 1 diabetes. For a woman whose glucose borderline exceeds the renal threshold, that luteal-phase bump could lower her GlycoMark by a few mcg/mL. A result drawn on day 22 of your cycle may look worse than one drawn on day 7, for reasons entirely unrelated to diet or medication adherence.

The clinical implication: if your GlycoMark result surprises your clinician, mention where you were in your cycle at the time of the draw.

PCOS: A High-Priority Condition for This Test

If you have polycystic ovary syndrome, GlycoMark is particularly relevant. PCOS affects an estimated 6-12% of reproductive-age women in the United States according to the CDC, and insulin resistance is present in roughly 70-80% of women with PCOS regardless of body weight. That insulin resistance drives postprandial glucose excursions that may not yet have pushed A1c above the diagnostic threshold.

A practical framework for PCOS monitoring: use GlycoMark alongside fasting insulin and HOMA-IR rather than relying on A1c alone. A woman with PCOS whose A1c is 5.6% but whose GlycoMark is 7 mcg/mL is showing evidence of postprandial hyperglycemia that warrants dietary intervention and closer glucose monitoring, even though both numbers technically fall within normal cut-points for their respective tests. This combination has not yet been formally validated in a PCOS-specific guideline, but the physiology supporting it is well-established in AACE/ACE guidance on PCOS and metabolic risk.

Perimenopause and Post-Menopause

Estrogen is broadly insulin-sensitizing. As estrogen declines during perimenopause, typically from your mid-40s onward, postprandial glucose variability increases. The Study of Women's Health Across the Nation (SWAN) showed that fasting glucose and insulin resistance both rise significantly during the menopausal transition, independent of changes in body weight. A perimenopausal woman who had perfectly normal glycemic markers at 40 may see her GlycoMark drift downward through her late 40s for hormonal reasons, not necessarily dietary ones.

Menopausal hormone therapy (MHT) may partially reverse this. Transdermal estradiol improves insulin sensitivity in postmenopausal women, which would be expected to support higher (better) GlycoMark values. A Cochrane review on HRT and diabetes risk noted that oral and transdermal estrogen reduce incident type 2 diabetes in postmenopausal women, though GlycoMark-specific outcomes have not been studied in MHT trials. That is another evidence gap worth acknowledging.

Pregnancy and GlycoMark: A Critical Exception

Standard GlycoMark reference ranges do NOT apply during pregnancy. This is not a footnote; it is the most important interpretive warning for women of reproductive age.

During normal, healthy pregnancy, 1,5-AG levels fall substantially, even in women with no diabetes. The mechanism is twofold. First, the renal threshold for glucose drops during pregnancy due to increased glomerular filtration rate, meaning glucose spills into urine at lower blood glucose levels, perhaps as low as 140-155 mg/dL rather than 180 mg/dL. Second, pregnancy increases glucosuria physiologically. Both mechanisms drive 1,5-AG out of the blood without any true hyperglycemia. A study in Diabetes Care found that median 1,5-AG levels in healthy pregnant women without gestational diabetes were approximately 3-5 mcg/mL, well below the non-pregnant normal threshold of 10 mcg/mL.

Gestational Diabetes and GlycoMark

Some researchers have explored whether 1,5-AG could help monitor postprandial glucose control in women with gestational diabetes (GDM). The short time-window of GlycoMark aligns well with the rapid dietary adjustments made during GDM management. However, no major clinical guideline, including the ACOG Practice Bulletin on Gestational Diabetes or the American Diabetes Association Standards of Care, currently recommends GlycoMark as a monitoring tool in pregnancy. The evidence base for its use in GDM is preliminary, and the confounding effect of pregnancy-related glucosuria makes interpretation unreliable without trimester-specific reference values, which do not yet exist in validated form.

What to Tell Your Clinician If You Are Pregnant or Recently Postpartum

If you had a GlycoMark drawn during pregnancy or within the first few weeks postpartum, tell your provider. A result of 4 mcg/mL in a non-pregnant woman would be concerning. The same result in a woman at 28 weeks of pregnancy may be entirely physiologic. The assay result should not be interpreted in isolation.

Postpartum, GlycoMark values typically return toward pre-pregnancy baselines within weeks of delivery, as glomerular filtration rate normalizes. Women with GDM who are being monitored for conversion to type 2 diabetes postpartum should have GlycoMark interpreted with their postpartum glucose tolerance test, not as a standalone marker.

What a Low GlycoMark Means (and What to Do)

A result below 6 mcg/mL means your glucose has been spiking above the renal threshold repeatedly over the past week or two. The lower the number, the more frequent or prolonged those spikes have been.

Common Causes in Women

• Uncontrolled or newly diagnosed type 2 diabetes
• Poorly timed or insufficient mealtime insulin in type 1 or type 2 diabetes
• PCOS-related postprandial hyperglycemia
• Perimenopausal glycemic deterioration
• High-glycemic-load dietary pattern (refined carbohydrates, sugary beverages, frequent large meals)
• Stress hyperglycemia (cortisol-driven glucose elevation)
• Steroid use, including high-dose inhaled corticosteroids

How to Raise GlycoMark (Improve Postprandial Control)

Raising GlycoMark means reducing how often and how high your glucose spikes. Specific approaches with evidence:

Dietary changes: Reducing rapidly digested carbohydrates is the most direct intervention. A randomized controlled trial published in Diabetes Care found that a low-glycemic-index diet reduced postprandial glucose excursions significantly compared to a high-fiber conventional diet. Breaking large meals into smaller, more frequent portions reduces peak glucose at any single sitting.

Meal sequencing: Eating vegetables and protein before carbohydrates at a given meal reduces peak postprandial glucose by 30-40% in some studies. Imai et al. Demonstrated this effect in a Japanese crossover study, a finding consistent with GlycoMark physiology.

Post-meal movement: Even a 10-minute walk after eating lowers postprandial glucose. A study in Diabetes Care showed that short post-meal walks were more effective at reducing 24-hour glucose excursions than a single 30-minute walk at another time of day.

Medication adjustments: If you are on metformin alone but experiencing postprandial spikes, your clinician may consider adding a GLP-1 receptor agonist such as semaglutide or liraglutide, both of which specifically blunt postprandial glucose. The SUSTAIN-6 trial demonstrated that semaglutide significantly reduced postprandial glucose excursions vs. Placebo. For women with PCOS and insulin resistance without a diabetes diagnosis, a GLP-1 agonist may not yet be the first line, but the option exists in clinical practice and is evolving.

What a High GlycoMark Means

A value well above 10 mcg/mL, say 15 or 20 mcg/mL, simply means your glucose has not been crossing the renal threshold repeatedly. This is the expected finding in a woman without diabetes who eats a balanced diet. It does not tell you anything additional about your metabolic health beyond the absence of frequent hyperglycemic excursions.

A paradoxically high GlycoMark can occur in women with very low kidney glucose filtration (certain kidney diseases where the renal threshold is raised). In that scenario, glucose may be high without spilling into urine, so 1,5-AG stays elevated even when blood glucose is not well controlled. This is uncommon but worth knowing if you have chronic kidney disease.

SGLT2 Inhibitors: A Major Confound

If you are taking an SGLT2 inhibitor, including empagliflozin (Jardiance), dapagliflozin (Farxiga), or canagliflozin (Invokana), your GlycoMark result is not interpretable using standard ranges. SGLT2 inhibitors work by blocking renal glucose reabsorption, which massively increases glucosuria at all glucose levels, not just above 180 mg/dL. Clinical studies confirm that 1,5-AG levels drop sharply with SGLT2 inhibitor use, often to <2 mcg/mL, even in patients with excellent glucose control. The test simply does not work as a glycemic marker while you are on this drug class. Tell your ordering clinician if you take one.

Who This Test Is Right For (and Who Should Skip It)

Good candidates for GlycoMark testing

• Women with type 1 or type 2 diabetes whose A1c looks acceptable but who describe frequent post-meal symptoms (shakiness, energy crashes, reactive hunger)
• Women with PCOS and borderline fasting glucose who want a better picture of postprandial glycemia
• Perimenopausal women noticing worsening glucose variability on continuous glucose monitor or fingerstick data
• Women newly started on a GLP-1 agonist or mealtime insulin who want a short-window check of response within 2 weeks
• Women with prediabetes (A1c 5.7-6.4%) who want to know whether postprandial spikes are occurring

Who should not rely on GlycoMark

• Pregnant women (reference ranges do not apply; see pregnancy section above)
• Women currently using an SGLT2 inhibitor
• Women with significant glucosuria from other causes (e.g., Fanconi syndrome)
• Women with advanced CKD stage 4-5 (altered renal handling of both glucose and 1,5-AG makes interpretation unreliable)

How GlycoMark Fits Alongside Other Glucose Tests

No single marker captures everything. Here is how GlycoMark complements other tests you may already have:

| Test | Time Window | What It Measures | GlycoMark Advantage | |---|---|---|---| | Fasting glucose | Snapshot | Overnight fasting glucose | GlycoMark catches post-meal spikes fasting glucose misses | | A1c | 8-12 weeks | Average glucose across all periods | GlycoMark detects recent changes faster | | Fructosamine | 2-3 weeks | Average glucose, similar window | GlycoMark is more sensitive to spikes, less to mild elevations | | CGM | Real-time | Every glucose fluctuation | CGM more granular, but GlycoMark is cheaper and requires no device |

The American Diabetes Association Standards of Medical Care acknowledges GlycoMark as a useful complementary marker when A1c is difficult to interpret, including in hemolytic anemia, hemoglobin variants, or recent blood transfusion.

Talking to Your Clinician About Your Result

Bring these four pieces of information when you discuss your GlycoMark:

1. What day of your menstrual cycle the blood was drawn (if you are in your reproductive years and still cycling)
2. Whether you are pregnant or recently postpartum
3. Whether you take an SGLT2 inhibitor or any corticosteroid
4. Your most recent A1c, fasting glucose, and fasting insulin (if available)

A GlycoMark of 7 mcg/mL means something different in a 28-year-old woman with PCOS who is 10 days into her luteal phase than it does in a 55-year-old postmenopausal woman with established type 2 diabetes. Context is not optional with this test. If your clinician ordered GlycoMark as a standalone result without that context, it is entirely reasonable to ask for a more complete interpretation before changing any treatment.

Ask specifically: "Is my result being interpreted against the standard non-pregnant adult range, and does that range apply to my current situation?" That single question may save you from unnecessary alarm or from false reassurance.

The current evidence base for GlycoMark in women is largely extrapolated from mixed-sex or male-predominant trials. As with many metabolic tests, the data in female-specific populations, particularly across the menstrual cycle and menopausal transition, remains thin. More granular normative data stratified by life stage would meaningfully improve how this otherwise useful test is applied.